TABLE 3.
The relationship between Beclin-1 and Bcl-2 expression with clinicopathological features of ESCC.
| Pathologic parameter | Case n | Beclin-1 expression | χ 2 | p-value | Bcl-2 expression | χ 2 | p-value | ||
|---|---|---|---|---|---|---|---|---|---|
| High n (%) | Low n (%) | High n (%) | Low n (%) | ||||||
| Gender | 0.54 | >0.05 | 0.15 | >0.05 | |||||
| Male | 65 | 24 (36.92) | 41 (63.08) | 36 (55.38) | 29 (44.62) | ||||
| Female | 37 | 11 (29.73) | 26 (70.27) | 19 (51.35) | 18 (48.65) | ||||
| Age | 1.07 | >0.05 | 1.07 | >0.05 | |||||
| ≤60 | 33 | 9 (27.27) | 24 (72.73) | 14 (42.42) | 19 (57.58) | ||||
| >60 | 69 | 26 (37.68) | 43 (62.32) | 41 (59.42) | 28 (40.58) | ||||
| Tumour diameter | 0.37 | >0.05 | 2.6 | >0.05 | |||||
| <3 cm | 57 | 21 (36.84) | 36 (63.16) | 34 (59.65) | 23 (40.35) | ||||
| ≥3 cm | 45 | 14 (31.11) | 31 (68.89) | 21 (46.67) | 24 (53.33) | ||||
| Differentiation | 3.5 | >0.05 | 1.83 | >0.05 | |||||
| Well and moderate | 60 | 25 (41.67) | 35 (58.33) | 29 (48.33) | 31 (51.67) | ||||
| Poor | 42 | 10 (23.81) | 32 (76.19) | 26 (61.90) | 16 (38.10) | ||||
| Pathological stage | 6.18 | <0.05 | 7.28 | <0.01 | |||||
| I–II | 44 | 21 (47.73) | 23 (57.27) | 17 (38.64) | 27 (61.36) | ||||
| III–IV | 58 | 14 (24.14) | 44 (75.86) | 38 (65.52) | 20 (34.48) | ||||
| Lymph node | 7.32 | <0.01 | 7.17 | <0.01 | |||||
| Positive | 70 | 18 (25.71) | 52 (74.29) | 44 (62.86) | 26 (37.14) | ||||
| Negative | 32 | 17 (53.13) | 15 (46.87) | 11 (34.38) | 21 (65.62) | ||||
| Depth of invasion | 0.86 | >0.05 | 5.37 | <0.05 | |||||
| T1, T2 | 46 | 18 (39.13) | 28 (60.87) | 19 (41.30) | 27 (58.70) | ||||
| T3, T4 | 56 | 17 (30.36) | 39 (69.64) | 36 (64.29) | 20 (35.71) | ||||
P < 0.05 was considered statistically significant. χ2 test for categorical variables.